Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 202
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024Expanded into Immunology with New Discovery Program of Oral KIT Inhibitors for First Indication in Chronic Spontaneous Urticaria; Development Candidate Selection Targeted for 202...
Discovery Program Of Oral Enanta Pharmaceuticals Enanta Pharmaceuticals Inc Healthcare Life Sciences Conference Exchange Commission Enrollment Ongoing Across Three
Source: pharmiweb.com